Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$116.44 USD
+0.95 (0.82%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $116.47 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Neurocrine Biosciences (NBIX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$166.48 | $193.00 | $128.00 | 44.15% |
Price Target
Based on short-term price targets offered by 25 analysts, the average price target for Neurocrine Biosciences comes to $166.48. The forecasts range from a low of $128.00 to a high of $193.00. The average price target represents an increase of 44.15% from the last closing price of $115.49.
Analyst Price Targets (25)
Broker Rating
Neurocrine Biosciences currently has an average brokerage recommendation (ABR) of 1.41 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 1.38 a month ago based on 26 recommendations.
Of the 27 recommendations deriving the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 3.7% of all recommendations. A month ago, Strong Buy represented 80.77%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 21 | 21 | 21 | 20 | 20 |
Buy | 1 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.41 | 1.38 | 1.38 | 1.46 | 1.46 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/10/2024 | Raymond James | Danielle Brill | Not Available | Moderate Buy |
10/8/2024 | Not Identified | Not Identified | Hold | Hold |
8/29/2024 | BMO Capital Markets | Evan Seigerman | Hold | Hold |
8/29/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
8/29/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
8/28/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
8/19/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/5/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
8/1/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/25/2024 | Needham & Company | Ami Fadia | Hold | Hold |
6/21/2024 | Mizuho SecuritiesUSA | Uy D Ear | Hold | Hold |
5/16/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
5/2/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
5/1/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
4/30/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
4/24/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.41 |
ABR (Last week) | 1.38 |
# of Recs in ABR | 27 |
Average Target Price | $166.48 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 1.48 |
NBIX FAQs
Neurocrine Biosciences, Inc. (NBIX) currently has an average brokerage recommendation (ABR) of 1.41 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms.
The average price target for Neurocrine Biosciences, Inc. (NBIX) is $166.48. The current on short-term price targets is based on 8 reports.
The forecasts for Neurocrine Biosciences, Inc. (NBIX) range from a low of $128 to a high of $193. The average price target represents a increase of $42.97 from the last closing price of $116.44.
The current UPSIDE for Neurocrine Biosciences, Inc. (NBIX) is 42.97%
Based on short-term price targets offered by 25 analysts, the average price target for Neurocrine Biosciences comes to $166.48. The forecasts range from a low of $128.00 to a high of $193.00. The average price target represents an increase of 44.15% from the last closing price of $115.49.